Needham & Company LLC Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note released on Thursday,Benzinga reports. They currently have a $207.00 price target on the specialty pharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Piper Sandler lowered their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Finally, StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Jazz Pharmaceuticals Stock Up 3.8 %

NASDAQ:JAZZ opened at $123.61 on Thursday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.02 and a current ratio of 4.26. The firm has a market cap of $7.63 billion, a P/E ratio of 17.41, a P/E/G ratio of 1.55 and a beta of 0.57. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The firm has a 50-day simple moving average of $110.64 and a two-hundred day simple moving average of $109.79.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. Foundry Partners LLC grew its position in Jazz Pharmaceuticals by 10.9% in the third quarter. Foundry Partners LLC now owns 3,362 shares of the specialty pharmaceutical company’s stock worth $375,000 after acquiring an additional 331 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 3.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 364 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Jazz Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company’s stock worth $13,035,000 after purchasing an additional 400 shares during the period. Natixis Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 7.6% during the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock valued at $2,544,000 after purchasing an additional 1,603 shares during the last quarter. Finally, CIBC Asset Management Inc purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at $209,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.